Severe Malaria Morbidity and Anemia Management

Severe malaria remains a leading cause of paediatric hospitalisation and mortality across sub-Saharan Africa and parts of Asia. The condition manifests with multi-organ dysfunction, most notably profound anaemia, cerebral involvement and respiratory distress. Severe malarial anaemia arises from parasite-mediated haemolysis, bone-marrow suppression and dyserythropoiesis, often compounded by concurrent nutritional deficiencies and comorbid infections. Management encompasses prompt parenteral antimalarial therapy, supportive care including blood transfusion, and monitoring for complications such as metabolic acidosis and hypoglycaemia. Beyond the acute phase, a high risk of recurrent malaria and hospital readmission persists, underscoring the importance of integrated strategies that bridge inpatient care with targeted post-discharge interventions and community-level prevention. Advances in modelling the long-term burden and refining transfusion and prophylactic guidelines have informed policies to reduce both in-hospital mortality and the hidden toll of post-discharge morbidity.

Research from Nature Portfolio

Recent studies have developed mathematical models to quantify the impact of post-discharge chemoprevention in children with severe malarial anaemia. These projections estimate that administering dihydroartemisinin-piperaquine at scheduled intervals after discharge could prevent tens of thousands of hospitalised malaria episodes annually across the highest-burden African countries. In moderate-to-high transmission settings, only two to five survivors of severe anaemia need to receive chemoprevention to avert one hospital admission, and fewer than 100 to prevent one death. Such modelling highlights the value of extending protective antimalarial therapy into the vulnerable post-hospitalisation period to curb recurrent disease and reduce health-system strain.

Severe Malaria Morbidity and Anemia Management publication trend

The graph below shows the total number of articles in severe malaria morbidity and anemia management across all publications each year (not limited to Nature Index journals).

Technical terms

Severe malarial anaemia (SMA): A life-threatening syndrome in which Plasmodium falciparum infection causes haemoglobin levels to fall below critical thresholds, typically <5 g/dL, due to red-cell destruction and impaired production.

Post-discharge malaria chemoprevention (PDMC): Scheduled administration of antimalarial drugs to children after hospital discharge aimed at preventing recurrent parasitaemia, reducing morbidity and averting readmissions.

Dihydroartemisinin-piperaquine (DP): An artemisinin-based combination therapy pairing a fast-acting artemisinin derivative with a long-acting partner drug, used both for acute treatment and as a prophylactic regimen.

References

1. Post-discharge malaria chemoprevention in children admitted with severe anaemia in malaria-endemic settings in Africa: a systematic review and individual patient data meta-analysis of randomised controlled trials. The Lancet Global Health (2023).
2. Projected health impact of post-discharge malaria chemoprevention among children with severe malarial anaemia in Africa. Nature Communications (2023).
3. Unusual clinical spectra of childhood severe malaria during malaria epidemic in eastern Uganda: a prospective study. Malaria Journal (2023).